You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 161 Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
161 Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors
Free

Authors

Citation

Sullivan P, Kumar R, Li W, et al
161 Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors
Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.161

Publication history

  • First published November 10, 2021.
Online issue publication 
March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.